Drug Investigation

, Volume 3, Supplement 3, pp 3–6 | Cite as

Intracellular Infections of the Respiratory Tract

  • Eduardo Rodríguez-Noriega


Intracellular pathogens are phagocytosed microorganisms that retain their pathogenic activity. Thus, antimicrobial treatment must provide sufficient intracellular drug concentrations within the phagocyte to be effective. Respiratory tract infections, such as atypical pneumonias, can be a result of organisms capable of survival and reproduction even within alveolar macrophages; antimicrobial therapy should, therefore, consist of agents with the ability to accumulate intracellularly.

Macrolides are effective treatment for atypical pneumonias in that they show excellent intracellular penetration. Among the macrolides, roxithromycin features a broad spectrum of activity and an improved pharmacokinetic profile compared with erythromycin. In addition, roxithromycin accumulates to a greater extent intracellularly and subcellularly than erythromycin. Thus, roxithromycin may provide an improved therapeutic outcome in the treatment of these infections.


Erythromycin Macrolides Roxithromycin Antimicrobial Chemotherapy Intracellular Pathogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson R, van Rensburg CEJ, Joone G, Lukey PT. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and rox-ithromycin. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 57–68, 1987PubMedGoogle Scholar
  2. Anon. Antibiotics for communtiy-acquired pneumonia in adults. Drug and Therapeutics Bulletin 26: 13–16, 1988Google Scholar
  3. Astarloa L, Maglio F, Cangelosi D, Garcia-Messina O. Roxithromycin in the treatment of atypical pneumonia in adult patients. British Journal of Clinical Practice 42(Suppl. 55): 94–95, 1988Google Scholar
  4. Bryskier A, Chantot JF, Lasc JC. Classification and structureactivity relationships of macrolides with emphasis on new developments. In Butzler & Kobayashi (Eds) Macrolides: a review with an outlook on future developments, pp. 7–21, Excerpta Medica, Amsterdam, 1986Google Scholar
  5. Carlier MB, Zenebergh A, Tulkens PM. Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 47–56, 1987PubMedGoogle Scholar
  6. Carlone NA, Ciuffini AM, Tullio V, Sassella D. Uptake of roxithromycin by mouse peritoneal macrophages. In Berkada & Kuemmerle (Eds) Progress in chemotherapy. Proceedings of the 15th International Congress of Chemotherapy, Istanbul, 19–24 July, 1987. Antimicrobial Section, Vol. 1, pp. 506–508, Ecomed, Landsberg, 1987Google Scholar
  7. Dette GA, Knothe H. Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leucocytes. Journal of Antimicrobial Chemotherapy 18: 73–82, 1986PubMedCrossRefGoogle Scholar
  8. Donowitz GR, Mandell GL. Acute pneumonia. In Mandell GL, et al. (Eds) Principles and practice of infectious diseases. 3rd ed., pp. 540–555, Churchill-Livingstone, New York, 1990Google Scholar
  9. Fernandez-MacLoughlin GJ, Lanoel JL, Stamboulian D, Savachian B. Roxithromycin in the treatment of atypical pneumonia. British Journal of Clinical Practice 42(Suppl. 55): 92–93, 1988Google Scholar
  10. Finch R. Treatment of respiratory tract infections with cephalosporin antibiotics. Drugs 34(Suppl. 2): 180–204, 1987PubMedCrossRefGoogle Scholar
  11. Green GM, Jakab GJ, Low RB, Davis GS. Defense mechanisms of the respiratory membrane. American Review of Respiratory Dieases 115: 479–514, 1977Google Scholar
  12. Herron JM. Roxithromycin in the therapy of Streptococcus pyogenes throat infections. Journal of Antimicrobial Chemotherapy 20(Suppl. B): 139–144, 1987PubMedGoogle Scholar
  13. Johnson JO, Hand WL, Francis JB, King-Thompson N, Corwin RW. Antibiotic uptake by alveolar macrophages. Journal of Laboratory and Clinical Medicine 95: 429–439, 1980PubMedGoogle Scholar
  14. Kees F, Grobecker H, Fourtillan JB, Tremblay D, Saint-Salvi B. Comparative pharmacokinetics of single dose roxithromycin (150mg) versus erythromycin stearate (500mg) in healthy volunteers. British Journal of Clinical Practice 42(Suppl. 55): 51, 1988Google Scholar
  15. Kirst HA, Sides GD, New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrobial Agents and Chemotherapy 33: 1419–1422, 1989PubMedCrossRefGoogle Scholar
  16. Labro MT, Amit N, Babin-Chevaye C, Hakim J. Synergy between Ru 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro. Antimicrobial Agents and Chemotherapy 30: 137–142, 1986PubMedCrossRefGoogle Scholar
  17. Martin JR, Johnson P, Miller MF. Uptake, accumulation and egress of erythromycin by tissue culture cells of human origin. Antimicrobial Agents and Chemotherapy 27: 314–319, 1985PubMedCrossRefGoogle Scholar
  18. Modai J. The clinical use of macrolides. Journal of Antimicrobial Chemotherapy 22(Suppl. B): 145–153, 1988PubMedGoogle Scholar
  19. Modai J. Empiric therapy of severe infections in adults. American Journal of Medicine 88(Suppl. 4A): 125–175, 1990Google Scholar
  20. Periti P, Mazzei T, Mini E, Novelli A. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various patho-physiological states (Part II). Clinical Pharmacokinetics 16: 261–282, 1989PubMedCrossRefGoogle Scholar
  21. Pocidalo J-J. Use of fluoroquinolones for intracellular pathogens. Reviews of Infectious Disease 11(Suppl. 5): S979–S984, 1989CrossRefGoogle Scholar
  22. Pocidalo J-J, Albert F, Desnottes JF, Kernbaum S. Intraphagocytic penetration of macrolides: in-vivo comparison of erythromycin and spiramycin. Journal of Antimicrobial Chemotherapy 16(Suppl. A): 167–173, 1985PubMedGoogle Scholar
  23. Prieto Prieto J, Minguez F, Ortega P, Corrales I, Ledesma V. Comparative study of the effects of roxithromycin and other macrolides on polymorphonuclear white cells in vitro. British Journal of Clinical Practice 42(Suppl. 55): 38–39, 1988Google Scholar
  24. Prokesch RC, Hand WL. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 21: 373–380, 1982PubMedCrossRefGoogle Scholar
  25. Raghoeber M, Lindeyer E, van den Berg W, van Ginneken CAM. On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leucocytes. Biochemical Pharmacology 37: 3221–3227, 1988CrossRefGoogle Scholar
  26. Research Committee of the British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome. Quarterly Journal of Medicine 239: 195–200, 1987Google Scholar
  27. Schwab JC, Mandell GL. The importance of penetration of antimicrobial agents into cells. Infectious Disease Clinics of North America 3: 461–467, 1989PubMedGoogle Scholar
  28. Segre G, Bianchi E, Zanolo G, Bartucci F, Sassella D. Influence of food on the bioavailability of roxithromycin versus erythromycin stearate. British Journal of Clinical Practice 42(Suppl. 55): 55–57, 1988Google Scholar
  29. Valcke Y, Pauwels R, Van Der Straeten M. Pharmacokinetics of antibiotics in the lungs. European Respiratory Journal 3: 715–722, 1990PubMedGoogle Scholar
  30. Yokoto T, Bhattacharya I. Synergy of bactericidal effect between roxithromycin and human leucocytes against S. aureus. British Journal of Clinical Practice 42(Suppl. 55): 40–42, 1988Google Scholar
  31. Young RA, Gonzales JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37: 8–41, 1989PubMedCrossRefGoogle Scholar
  32. Zini R, Fournet MP, Barre J, Tremblay D, Tillement JP. In vitro study of roxithromycin binding to serum proteins and erythrocytes in humans. British Journal of Clinical Practice 42(Suppl. 55): 54, 1988Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Eduardo Rodríguez-Noriega
    • 1
  1. 1.Division of Infectious DiseasesUniversity of GuadalajaraJaliscoMexico

Personalised recommendations